TK2 Antibody

What is Thymidine Kinase 2 (TK2) and what is its biological significance?

Thymidine kinase 2 (TK2) is a nuclear DNA-encoded mitochondrial enzyme that catalyzes the phosphorylation of pyrimidine deoxynucleosides (thymidine, deoxycytidine, and deoxyuridine) within the mitochondrial matrix. TK2 plays a crucial role in the mitochondrial DNA (mtDNA) salvage pathway, which is essential for maintaining balanced mitochondrial deoxyribonucleotide triphosphate (dNTP) pools required for mtDNA replication and repair .

In non-replicating cells where cytosolic dNTP synthesis is downregulated, mtDNA synthesis becomes solely dependent on TK2 and deoxyguanosine kinase (DGUOK) . The highest levels of TK2 expression are observed in testis and ovary tissues, though it functions in mitochondria across various cell types .

What types of TK2 antibodies are available for research purposes?

Based on the search results, multiple types of TK2 antibodies are commercially available for research:

There are approximately 45 different TK2 antibody products available across 18 suppliers, with varying specificities to different regions of the protein (N-terminal, middle region, C-terminal) . These antibodies are available in different formats, including unconjugated and conjugated versions (with biotin, fluorescent dyes, etc.) .

What is the molecular weight of TK2 protein, and how does this affect antibody selection?

When selecting antibodies, researchers should review the validation data provided by manufacturers to confirm that the antibody detects TK2 at the expected molecular weight in their experimental system, as post-translational modifications or splice variants may affect migration patterns on SDS-PAGE.

What are the optimal applications for TK2 antibodies in research?

Based on the search results, TK2 antibodies are primarily validated for the following applications:

• Western Blotting (WB): Most commonly validated application; useful for protein expression analysis and semi-quantitative studies

• Enzyme-Linked Immunosorbent Assay (ELISA): Suitable for quantitative analysis of TK2 levels in biological samples

• Immunohistochemistry (IHC): Useful for localization studies in tissue sections, particularly in paraffin-embedded samples

• Flow Cytometry (FCM): Some antibodies are validated for intracellular staining of TK2 in flow cytometry applications

When designing experiments, researchers should choose antibodies specifically validated for their intended application. For example, epitope availability may differ between denatured (WB) and native (ELISA) conditions.

How should I design control experiments when using TK2 antibodies?

Proper controls are essential for interpreting results with TK2 antibodies:

• Positive controls: Include samples known to express TK2 (e.g., testis or ovary tissue extracts, which show high expression)

• Negative controls:

  • Primary antibody controls: Isotype-matched irrelevant antibodies

  • Secondary antibody controls: Samples without primary antibody incubation

• Knockdown/knockout validation: When available, TK2 siRNA knockdown samples can provide strong specificity validation

• Cross-reactivity controls: If working with multiple species, include samples from non-target species to assess cross-reactivity

For flow cytometry specifically, unlabelled samples without primary and secondary antibodies should be used as blank controls, and isotype control antibodies should be used under identical conditions to determine background staining levels .

What are the optimal sample preparation methods for TK2 detection?

Sample preparation depends on the application:

For Western blotting:

• Use standard cell lysis buffers containing protease inhibitors

• Load adequate protein (typically 30 μg per lane as used in validation studies)

• Reduce samples appropriately before SDS-PAGE

• Transfer to nitrocellulose membrane at 150 mA for 50-90 minutes (based on validation protocols)

• Block with 5% non-fat milk in TBS for 1.5 hours at room temperature

For Flow Cytometry:

• Fix cells with 4% paraformaldehyde

• Permeabilize with appropriate permeabilization buffer

• Block with 10% normal serum (matching secondary antibody species)

• Incubate with TK2 antibody (approximately 1 μg per 10^6 cells)

• Use appropriate fluorophore-conjugated secondary antibodies

For IHC:

• Use standard formalin-fixed, paraffin-embedded tissue processing

• Perform appropriate antigen retrieval

• A dilution of 1:200 has been validated for certain antibodies in IHC applications

How can I validate the specificity of TK2 antibodies in my experimental system?

Validating antibody specificity is crucial for reliable results:

• Multiple antibodies approach: Use antibodies targeting different epitopes of TK2 and compare results

• Genetic validation:

  • Compare results in wild-type vs. TK2 knockdown/knockout samples

  • Overexpression studies with tagged TK2 can confirm antibody specificity

• Cross-reactivity assessment:

  • If the antibody claims cross-reactivity with multiple species, verify using samples from each species

  • Compare observed molecular weight with predicted size for each species

• Peptide competition: If available, pre-incubate the antibody with the immunizing peptide to confirm specific binding is blocked

• Expression pattern analysis: Compare observed TK2 staining pattern with known subcellular localization (mitochondrial) and tissue expression patterns (higher in testis and ovary)

What are common technical problems when using TK2 antibodies and how can they be resolved?

For flow cytometry specifically, when analyzing intracellular TK2, ensure proper fixation and permeabilization. The validation data shows successful staining of Jurkat cells using 4% paraformaldehyde fixation and appropriate permeabilization buffer .

How can TK2 antibodies be used to study mitochondrial DNA depletion syndromes?

TK2 deficiency causes mitochondrial DNA depletion syndrome (MTDPS2), a rare autosomal recessive disorder characterized by progressive muscle weakness, respiratory insufficiency, and often early mortality . TK2 antibodies can be valuable tools in researching this condition:

• Diagnostic applications:

  • IHC analysis of muscle biopsies to assess TK2 protein levels

  • Western blot quantification to correlate protein expression with disease severity

• Pathophysiological studies:

  • Investigate the relationship between TK2 protein levels and mtDNA depletion (55-90% depletion reported in patients)

  • Study the impact of specific TK2 mutations on protein expression and stability

• Therapeutic development:

  • Monitor TK2 protein expression in response to experimental treatments like nucleoside replacement therapy

  • Evaluate protein restoration in gene therapy approaches

Recent clinical studies indicate that TK2 deficiency may be underdiagnosed, with approximately 60% of cases being late-onset variants . Using TK2 antibodies in research and diagnostic workflows can help identify more cases, particularly those with atypical presentations.

What experimental approaches are recommended for studying TK2's role in cancer and therapeutic nucleoside analogs?

TK2 has been implicated in cancer biology and may play a role in activating anticancer nucleoside analogs . Here are recommended experimental approaches:

• Expression analysis:

  • Compare TK2 protein levels between normal and cancer tissues using IHC or Western blotting

  • Correlate expression with clinical outcomes in patient samples

• Functional studies:

  • Use siRNA knockdown of TK2 (shown to sensitize tumor cells to gemcitabine)

  • Compare nucleoside analog activation in cells with varying TK2 expression levels

• Subcellular localization:

  • Combine TK2 antibodies with mitochondrial markers in immunofluorescence studies

  • Investigate potential changes in localization during cancer progression or treatment

• Drug resistance mechanisms:

  • Evaluate TK2 expression in drug-resistant versus sensitive cancer cell lines

  • Investigate correlation between TK2 activity and resistance to nucleoside analog therapies

What are the methodological considerations when using TK2 antibodies in experimental design with a quasi-experimental or true experimental approach?

When designing studies with TK2 antibodies, consider the following methodological aspects based on experimental design principles:

For true experimental designs (characterized by random assignment and manipulation of independent variables) :

• Clearly define research questions about TK2's role in your biological system

• Establish appropriate control groups (e.g., wild-type vs. TK2 knockout)

• Randomly assign experimental units to treatment conditions

• Manipulate the independent variable (e.g., treatment affecting TK2 expression)

• Use TK2 antibodies to measure the dependent variable (protein expression/localization)

• Use appropriate statistical analysis methods (t-tests or ANOVA depending on group numbers)

For quasi-experimental designs (without full randomization) :

• Consider potential confounding variables that might influence TK2 expression

• Use matching or statistical control techniques to minimize bias

• Employ interrupted time-series designs to evaluate changes in TK2 expression over time

• Establish baseline measurements before intervention when possible

• Be cautious about making causal inferences about factors affecting TK2

Remember that quasi-experimental designs, while valuable, have limitations in establishing causality compared to true experimental designs . The choice between them depends on practical and ethical constraints of your research question.

How should I select the most appropriate TK2 antibody for my specific research question?

Selection criteria should include:

• Epitope location: Choose antibodies targeting regions relevant to your research question:

  • N-terminal antibodies (aa 8-38) may be useful for detecting full-length protein

  • Middle region antibodies for general detection

  • C-terminal antibodies if studying specific domains or post-translational modifications

• Validation data: Examine Western blot images, IHC staining patterns, and flow cytometry histograms provided by manufacturers

• Species reactivity: Verify cross-reactivity with your experimental species (human, mouse, etc.)

• Application compatibility: Ensure validation for your specific application (WB, IHC, etc.)

• Clonality consideration:

  • Polyclonal antibodies: Better for detection of denatured proteins, recognize multiple epitopes

  • Monoclonal antibodies: Higher specificity, better for distinguishing specific isoforms

Review validation data carefully - for example, one antibody detected TK2 at approximately 25 kDa despite the calculated molecular weight being 31 kDa .

What are the recommended storage and handling conditions for TK2 antibodies to maintain optimal performance?

Based on manufacturer recommendations from the search results :

• Storage temperature:

  • Store at -20°C for long-term (up to one year from receipt)

  • After reconstitution, store at 4°C for short-term use (one month)

  • For extended storage after reconstitution, aliquot and freeze at -20°C (up to six months)

• Reconstitution:

  • For lyophilized antibodies, add 0.2 ml distilled water to yield a concentration of 500 μg/ml

  • Allow complete dissolution before use

• Handling precautions:

  • Avoid repeated freeze-thaw cycles (create single-use aliquots)

  • Some antibodies contain sodium azide (0.09% W/V) , which is toxic and requires careful handling

  • Work with antibodies on ice when possible

• Expiration considerations:

  • Many antibodies have a shelf life of 6 months ; check manufacturer specifications

  • Document date of reconstitution and use before expiration

Following these storage and handling guidelines will help maintain antibody sensitivity and specificity across experiments.

How can I use TK2 antibodies to investigate mitochondrial dysfunction in neurodegenerative diseases?

TK2 deficiency has been associated with neurodegenerative manifestations, and TK2 antibodies can be valuable tools in investigating broader mitochondrial dysfunction:

• Comparative expression analysis:

  • Use IHC to compare TK2 expression in brain tissues from neurodegenerative disease patients versus controls

  • Validated antibodies have been used successfully in cerebral cortex tissue

• Co-localization studies:

  • Combine TK2 antibodies with markers of mitochondrial dysfunction

  • Investigate potential changes in TK2 localization during neurodegeneration

• Intervention studies:

  • Monitor TK2 expression in response to treatments targeting mitochondrial function

  • Correlate changes in TK2 levels with improvements in disease markers

• Biomarker development:

  • Investigate whether TK2 protein levels in accessible tissues correlate with disease progression

  • Evaluate TK2 as part of a panel of mitochondrial dysfunction markers

Recent research has shown that TK2 deficiency can present with late-onset symptoms involving the central nervous system, expanding our understanding of its role in neurological health .

What are the methodological considerations when using TK2 antibodies in combination with other mitochondrial markers?

When designing multiplex experiments combining TK2 antibodies with other mitochondrial markers:

• Antibody compatibility:

  • Ensure primary antibodies are raised in different host species to avoid cross-reactivity

  • If using antibodies from the same species, consider directly conjugated antibodies or sequential staining protocols

• Localization precision:

  • TK2 is localized to the mitochondrial matrix; choose complementary markers for different mitochondrial compartments

  • Consider super-resolution microscopy techniques for precise co-localization analysis

• Dynamic assessments:

  • Combine with functional mitochondrial assays (membrane potential, respiration)

  • Correlate TK2 levels with markers of mtDNA maintenance (copy number, deletion load)

• Sample preparation optimization:

  • Mitochondrial preservation is critical; optimize fixation conditions

  • Consider using mitochondrial isolation procedures for biochemical analyses

• Controls for multiplex experiments:

  • Include single-stained controls for each antibody

  • Use appropriate blocking to prevent non-specific binding

How can I design experiments to study the relationship between TK2 expression and mtDNA maintenance in different cellular stress conditions?

To investigate TK2's role during cellular stress:

• Stress model selection:

  • Oxidative stress (H₂O₂, paraquat)

  • Nutrient deprivation (glucose or serum starvation)

  • Hypoxia/reperfusion models

  • Treatment with mtDNA depletion agents (ethidium bromide, ddC)

• Time-course analysis:

  • Monitor TK2 protein levels at different time points using Western blot

  • Correlate with changes in mtDNA copy number (qPCR) and cell viability

• Subcellular fractionation:

  • Isolate mitochondria to assess TK2 levels specifically in the mitochondrial fraction

  • Compare with total cellular TK2 to detect potential translocation

• Rescue experiments:

  • Overexpress wild-type TK2 in stressed cells

  • Assess whether increased TK2 levels can rescue mtDNA depletion or cellular dysfunction

• Multi-parameter analysis:

  • Combine TK2 antibody-based detection with measurements of:

    • mtDNA copy number (qPCR)

    • mtDNA integrity (long-range PCR)

    • Mitochondrial function (oxygen consumption, ATP production)

This comprehensive approach can elucidate TK2's role in maintaining mitochondrial genome integrity under various stress conditions.